Sohonos (palvarotene)
Prior authorization and quantity/ specialty pharmacy requirements for Sohonos (palvarotene) for treatment of fibrodysplasia ossificans progressiva (FOP) for specified pediatric and adult ages; includes initial and continuation criteria, quantity limit, approval duration, and specialty dispensing requirement.
Reviewed at August P&T with no clinical changes; effective date set to 09/01/2025.
Coverage Summary
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.